Sharon Osbourne admits 'I didn't want to go this thin' as she shows off drastic weight loss
| Last updated
Featured Image Credit: Talk TV / Art Streiber/CBS via Getty Images
Sharon Osbourne has opened up about her drastic weight loss, admitting that she 'didn’t want to go this thin'.
The 70-year-old TV personality revealed the results of her weight loss in an interview on Wednesday.
Back in June, Sharon announced she had lost over two stone after using the controversial weight-loss injection Ozempic.
The former X Factor judge said she used the jabs over a four-month period, however she admitted they left her feeling nauseous after using them every day and insisted it was not a ‘quick fix’.
“In my life, the heaviest I was 230 pounds and I’m now under a hundred and I want to maintain about 105 because I’m too skinny. But I’m trying to have a healthy balance,” she told E! News.
Sharon has since stopped using the drug, with her telling Piers Morgan on TalkTV alongside her family: “It’s just time to stop, I didn’t actually want to go this thin but it just happened. I'll probably put it all on again soon!”
During a discussion on The Talk in June about losing weight by using injections, Sharon revealed her first-hand experience with them.
'But I took (the injection.) I took it for four months and I lost 30 pounds, but like everything, there’s always no quick recipe.
“I was very sick for a couple of months. The first couple of months, I just felt nauseous.
"Every day I felt nauseous, my stomach was upset, whatever.
“But listen, I took it for four months, I lost 30 pounds. I’ve just shoved two chips in my mouth, while we had the break, and I eat normally now and I haven’t put on a pound. Nothing.”
The drug semaglutide - which was first released in 2017 - has become a popular choice in Hollywood as a quick fix but was originally intended to treat weight-related issues like type 2 diabetes.
Patients began to notice that the drug not only helped with their health issues, but was also a quick and easy way to shed a few extra pounds.
Fast-forward four years and, in 2021, semaglutide was officially approved as a weight loss treatment leading to ‘off-label prescribing’.
Manufactured by Danish pharmaceutical giant, Novo Nordisk, the drug has since been rebranded into two categories - 'Ozempic' for diabetes issues and 'Wegovy' for weight loss and management.